INT156108

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 0.59
Pain Relevance 1.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
joint 1
arm 1
cleft 1
TSS (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 128 99.36 Very High Very High Very High
Adalimumab 129 98.16 Very High Very High Very High
Etanercept 57 79.28 Quite High
antagonist 23 73.48 Quite High
rheumatoid arthritis 108 67.00 Quite High
Rheumatism 5 64.40 Quite High
Pain 6 55.52 Quite High
Infliximab 130 50.00 Quite Low
headache 6 50.00 Quite Low
visual analogue scale 2 45.92 Quite Low
Disease Link Frequency Relevance Heat
Disease 54 92.24 High High
Headache Disorders 1 69.12 Quite High
Rheumatoid Arthritis 113 67.00 Quite High
Rheumatic Diseases 5 64.40 Quite High
Headache 3 50.00 Quite Low
Pain 4 43.84 Quite Low
Disease Progression 4 20.96 Low Low
Low Back Pain 25 5.00 Very Low Very Low Very Low
Infection 22 5.00 Very Low Very Low Very Low
Seronegative Spondarthritis 21 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CONCLUSIONS: In this retrospective study, the authors demonstrate the efficacy of TSS in the treatment of intractable headaches in patients who present with pituitary microadenomas (nonsecreting and hypersecretory) and Rathke cleft cysts.


Regulation (efficacy) of TSS in cleft
1) Confidence 0.23 Published 2009 Journal J. Neurosurg. Section Body Doc Link 19012490 Disease Relevance 0.07 Pain Relevance 0
The median changes of TSS at week 54 were 0.0 in the 3 and 10 mg/kg groups (Fig. 3); the progression of joint damage was inhibited in most of the patients.
Regulation (changes) of TSS in joint
2) Confidence 0.05 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2759008 Disease Relevance 0 Pain Relevance 0
In the 6 mg/kg group, the median change in TSS was 0.5, significantly different to that at 10 mg/kg group.
Regulation (change) of TSS
3) Confidence 0.02 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2759008 Disease Relevance 0 Pain Relevance 0
To determine if there was a slowing of radiographic progression in subjects who were ACR20 non-responders at week 12, but became responders at week 24 compared with week 12 responders, the mean change in TSS and the percentage of non-progressors were evaluated at week 52.
Regulation (change) of TSS
4) Confidence 0.01 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2566536 Disease Relevance 0 Pain Relevance 0.21
The radiographic outcome at week 52 was evaluated using the mean change in total Sharp score (TSS) and the percentage of non-progressors (TSS change ?
Regulation (change) of TSS
5) Confidence 0.01 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2566536 Disease Relevance 0.33 Pain Relevance 0.21
The differences in radiographic progression for patients treated with adalimumab versus MTX alone at Year 1 were even more marked at the end of Year 2, with an accumulated TSS change of 10.4 in the MTX monotherapy arm versus 5.5 in the adalimumab monotherapy arm and 1.9 in the combination arm.
Regulation (change) of TSS in arm associated with adalimumab and methotrexate
6) Confidence 0.01 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.19 Pain Relevance 1.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox